Seeking Alpha

Novo Nordisk (NVO -2.1%) shares slip after announcing the FDA extended the regulatory review...

Novo Nordisk (NVO -2.1%) shares slip after announcing the FDA extended the regulatory review period by three months for the drug maker's ultra-long-acting insulins degludec and insulin degludec/insulin aspart for the treatment of type 1 and type 2 diabetes.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|